Whittier Trust Co. increased its holdings in ICON Public Limited (NASDAQ:ICLR – Get Rating) by 2,555.6% in the 1st quarter, Holdings Channel reports. The fund owned 1,434 shares of the medical research company’s stock after purchasing an additional 1,380 shares during the period. Whittier Trust Co.’s holdings in ICON Public were worth $349,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the company. Todd Asset Management LLC increased its holdings in shares of ICON Public by 33.1% during the 1st quarter. Todd Asset Management LLC now owns 69,766 shares of the medical research company’s stock valued at $16,950,000 after acquiring an additional 17,354 shares during the last quarter. FDx Advisors Inc. lifted its position in shares of ICON Public by 1.7% in the 4th quarter. FDx Advisors Inc. now owns 19,191 shares of the medical research company’s stock worth $5,943,000 after acquiring an additional 320 shares during the period. SkyView Investment Advisors LLC bought a new stake in shares of ICON Public in the 4th quarter worth approximately $409,000. Dorsey Wright & Associates bought a new stake in shares of ICON Public in the 4th quarter worth approximately $4,711,000. Finally, We Are One Seven LLC lifted its position in shares of ICON Public by 2.8% in the 4th quarter. We Are One Seven LLC now owns 7,803 shares of the medical research company’s stock worth $1,122,000 after acquiring an additional 212 shares during the period. 89.41% of the stock is owned by institutional investors and hedge funds.
ICON Public Stock Down 1.6 %
NASDAQ ICLR opened at $221.09 on Friday. The business has a fifty day moving average price of $215.29 and a two-hundred day moving average price of $233.95. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.13 and a quick ratio of 1.13. ICON Public Limited has a fifty-two week low of $196.34 and a fifty-two week high of $313.00. The stock has a market capitalization of $17.99 billion, a PE ratio of 88.79, a PEG ratio of 1.10 and a beta of 0.95.
ICON Public (NASDAQ:ICLR – Get Rating) last announced its quarterly earnings results on Wednesday, April 27th. The medical research company reported $2.60 EPS for the quarter, beating analysts’ consensus estimates of $2.48 by $0.12. ICON Public had a return on equity of 11.33% and a net margin of 2.58%. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.88 billion. During the same period in the prior year, the company earned $2.06 EPS. Equities analysts expect that ICON Public Limited will post 10.67 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
ICLR has been the subject of several analyst reports. Citigroup cut their target price on ICON Public from $315.00 to $290.00 and set a “buy” rating for the company in a research report on Friday, July 8th. Guggenheim assumed coverage on ICON Public in a research note on Monday, May 23rd. They issued a “buy” rating and a $285.00 target price for the company. Barclays lowered their target price on ICON Public from $250.00 to $245.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 13th. Deutsche Bank Aktiengesellschaft decreased their price objective on ICON Public from $310.00 to $285.00 and set a “buy” rating for the company in a research note on Thursday, July 14th. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $285.00 price objective on shares of ICON Public in a research note on Friday, May 13th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $281.56.
About ICON Public
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
See Also
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICON Public Limited (NASDAQ:ICLR – Get Rating).
Receive News & Ratings for ICON Public Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ICON Public and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
